Middle East & Africa Kidney Cancer Therapeutics & Diagnostics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Middle East and Africa Kidney Cancer Therapeutics & Diagnostics Market Analysis

The Middle East and Africa kidney cancer therapeutics and diagnostics market is projected to grow at a CAGR of 5.2% over the forecast period.

The COVID-19 pandemic affected healthcare systems and resulted in the interruption of general care in many healthcare facilities. This situation exposed patients with cancer to significant risks. According to the study published in the Journal of Clinical Oncology in June 2022, patients with cancer were reported to be a vulnerable population that suffered from SARS-CoV-2 infection and the pandemic's impact on healthcare systems during the COVID-19 pandemic. There were significant negative implications for patients with kidney cancer when medical attention was diverted exclusively to COVID-19 patients. Thus, during the COVID-19 pandemic, the kidney cancer therapeutics and diagnostics market was severely impacted. Since restrictions were removed, the market has been recovering strongly. Over the past two years, a rise in hospital visits, the reopening of clinics, and the diagnostics lab have been driving the market recovery.

The market expected show rapid growth due to the rising number of kidney cancer cases in the region and the increasing R&D expenditure of pharmaceutical companies. Excessive smoking, an increase in obesity levels , and increased intake of alcohol are some of the causes of kidney cancer in the region. According to the study published in Urology Annals in March 2022, in Saudi Arabia, kidney tumor incidence and mortality account for 3.4% and 2.4% of the population, respectively, with males and the elderly being more affected. Renal cell carcinoma accounts for approximately 85% of all kidney tumors (RCC). Though the prevalence of kidney cancer cases in the region is less compared to the other region of the world, the incidence is still increasing during the recent years, due to lifestyle changes.

Moreover, various initiatives taken by the market players are likely to support the growth of the market. For instance, in March 2022, in the United Arab Emirates AstraZeneca pharmaceutical hosted a worldwide summit to help change the trajectory of cancer diagnosis, treatment, and cure.

Factors such as rising burden of kidney cancer and product launches by market players are expected to contribute to market growth over the forecast period in the Middle East and African region. However, the high cost associated with the treatment may restrain the market growth.

Middle East and Africa Kidney Cancer Therapeutics & Diagnostics Market Trends

This section covers the major market trends shaping the MEA Kidney Cancer Therapeutics & Diagnostics Market according to our research experts:

Renal Cancer Carcinoma is Expected to Hold a Major Share in the Studied Market Over The Forecast Period.

Middle East and Africa Kidney Cancer Therapeutics & Diagnostics Industry Segmentation

As per the scope of the report, kidney cancer is a type of cancer that starts in kidney cells. Kidney cancer therapeutics and diagnostics involve therapy and diagnostics methods used to treat renal cancer. The Middle East and Africa, the Kidney Cancer therapeutics & diagnostics market, is segmented by cancer Type (Renal Cancer Carcinoma, Clear Cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, and Others), Component (Drugs (Therapeutic Class, Pharmacologic Class), diagnostics (Biopsy, Imaging Tests, Others), and geography (Saudi Arabia, United Arab Emirates, South Africa, and Rest of Middle East and Africa). The report offers the value (in USD million) for the above segments.